Clinical Trial Update: Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating pyrotinib combined with etoposide for HER2-positive advanced breast cancer is in Phase II with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Etoposide (Etoposide)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN